This study assessed the comparative efficacy and safety of tumor necrosis factor alpha (TNF-α) inhibitors in treating noninfectious uveitis (NIU).
Methods:
A comprehensive search was performed in PubMed, Embase, Cochrane Library, ClinicalTrials.gov, China National Knowledge Infrastructure, and Wanfang Database from January 2010 to March 2024. The outcomes measured included inflammation improvement, visual acuity (VA) improvement, corticosteroid (CS)-sparing effect, central macular thickness (CMT) reduction, and adverse event incidence. Meta-analyses were conducted using RevMan 5.4 and Stata 16 software.
Results:
A total of 40 studies were included, involving 3,250 patients. TNF-α inhibitors showed a 90.4% inflammation improvement rate [95% confidence interval (CI): 0.770–0.987], 35.2% VA improvement (95% CI: 0.152–0.553), 55.3% CS-sparing effect (95% CI: 0.297–0.796), and CMT reduction of 62.37 µm (95% CI: 45.41–79.32 µm). Adverse events occurred in 24.0% of patients (95% CI: 0.170–0.310). No significant differences were observed between adalimumab and infliximab in inflammation improvement (P = 0.60) or CMT reduction (P = 0.55), but infliximab had higher adverse event rates (P = 0.0001; relative risk = 1.71, 95% CI: 1.30–2.24).
Conclusions:
This meta-analysis demonstrates that TNF-α inhibitors significantly improve inflammation, VA, and reduce CMT and CS use in NIU. While adalimumab and infliximab exhibit comparable efficacy, infliximab is associated with a higher adverse event rate, highlighting the need for personalized treatment.
UmazumeA, OhguroN, OkadaAA, et al.Prevalence and incidence rates and treatment patterns of non-infectious uveitis in Japan: Real-world data using a claims database. Jpn J Ophthalmol, 2021; 65(5):657–665; doi: 10.1007/s10384-021-00850-8
2.
ZhangCH, HuSX, PanYT, et al.Process in the treatment of non-infectious uveitis with Adalimumab. Guoji Yanke Zazhi (Int Eye Sci), 2021; 21(9):1561–1565; doi: 10.3980/j.issn.1672-5123.2021.9.14
3.
Burek-MichalskaA, Turno-KręcickaA. Adalimumab in the treatment of non-infectious uveitis. Adv Clin Exp Med, 2020; 29(10):1231–1236; doi: 10.17219/acem/125431
EspinosaG, HerrerasJM, Muñoz-FernándezS, et al.Recommendations statement on the immunosuppressive treatment of non-infectious, non-neoplastic, non-anterior uveitis. Med Clin (Barc), 2020; 155(5):220.e1–e12; doi: 10.1016/j.medcli.2019.10.023
6.
PleyerU, StübigerN. New pharmacotherapy options for noninfectious posterior uveitis. Expert Opin Biol Ther, 2014; 14(12):1783–1799; doi: 10.1517/14712598.2014.956074
7.
LeclercqM, DesboisAC, DomontF, et al.Biotherapies in uveitis. J Clin Med, 2020; 9(11):3599; doi: 10.3390/jcm9113599
8.
SuhlerEB, LowderCY, GoldsteinDA, et al.Adalimumab therapy for refractory uveitis: Results of a multicentre, open-label, prospective trial. Br J Ophthalmol, 2013; 97(4):481–486; doi: 10.1136/bjophthalmol-2012-302292
9.
Busto-IglesiasM, Rodríguez-MartínezL, Rodríguez-FernándezCA, et al.Perspectives of therapeutic drug monitoring of biological agents in non-Infectious uveitis treatment: A review. Pharmaceutics, 2023; 15(3):766; doi: 10.3390/pharmaceutics15030766
10.
JabsDA, NussenblattRB, RosenbaumJT, Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol, 2005; 140(3):509–516; doi: 10.1016/j.ajo.2005.03.057
11.
Tang Lee SayTL, YangV, FingretJM, et al.Adalimumab in patients with vision-threatening uveitis: Real-world clinical experience. BMJ Open Ophthalmol, 2021; 6(1):e000819; doi: 10.1136/bmjophth-2021-000819
12.
SenES, SharmaS, HinchcliffeA, et al.Use of adalimumab in refractory non-infectious childhood chronic uveitis: Efficacy in ocular disease—A case cohort interventional study. Rheumatology (Oxford), 2012; 51(12):2199–2203; doi: 10.1093/rheumatology/kes212
13.
MercierAE, RibeiroE, KorobelnikJF, et al.Efficacy of anti-TNF-α therapy for the treatment of non-infectious uveitis: A retrospective study of 21 patients. Ocul Immunol Inflamm, 2018; 26(3):477–484; doi: 10.1080/09273948.2016.1236968
14.
MagliA, ForteR, NavarroP, et al.Adalimumab for juvenile idiopathic arthritis-associated uveitis. Graefes Arch Clin Exp Ophthalmol, 2013; 251(6):1601–1606; doi: 10.1007/s00417-013-2275-x
15.
JinY, LuS, LinY, et al.The efficacy and safety of TNF inhibitor (golimumab) as salvage treatment in patients with refractory noninfectious uveitis. Inflammopharmacology, 2022; 30(4):1363–1368; doi: 10.1007/s10787-022-01019-6
16.
Díaz-LlopisM, SalomD, Garcia-de-VicuñaC, et al.Treatment of refractory uveitis with adalimumab: A prospective multicenter study of 131 patients. Ophthalmology, 2012; 119(8):1575–1581; doi: 10.1016/j.ophtha.2012.02.018
17.
ZanninME, BiroloC, GerloniVM, et al.Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian Registry. J Rheumatol, 2013; 40(1):74–79; doi: 10.3899/jrheum.120583
18.
Ucan GunduzG, YalcinbayirO, CekicS, et al.Anti-tumor necrosis factor treatment in the management of pediatric noninfectious uveitis: Infliximab versus adalimumab. J Ocul Pharmacol Ther, 2021; 37(4):236–240; doi: 10.1089/jop.2020.0081
19.
SimoniniG, TaddioA, CattaliniM, et al.Prevention of flare recurrences in childhood-refractory chronic uveitis: An open-label comparative study of adalimumab versus infliximab. Arthritis Care Res (Hoboken), 2011; 63(4):612–618; doi: 10.1002/acr.20404
20.
MesenS, OzerMD, BaturM. Comparative results of use and switching of anti-TNF-alpha agents in adult Behçet’s uveitis. Indian J Ophthalmol, 2024; 72(Suppl 3):S521–S528; doi: 10.4103/IJO.IJO_2011_23
21.
MaaloufG, AndrillonA, LeclercqM, et al.Lower relapses rate with infliximab versus adalimumab in sight-threatening uveitis: A multicenter study of 330 patients. Am J Ophthalmol, 2022; 238:173–180; doi: 10.1016/j.ajo.2022.02.002
22.
LeclercqM, AndrillonA, MaaloufG, et al.Anti-tumor necrosis factor α versus tocilizumab in the treatment of refractory uveitic macular edema: A multicenter study from the French Uveitis Network. Ophthalmology, 2022; 129(5):520–529; doi: 10.1016/j.ophtha.2021.11.013
23.
KunimiK, UsuiY, AsakageM, et al.Anti-TNF-α therapy for refractory uveitis associated with Behçet’s syndrome and sarcoidosis: A single center study of 131 patients. Ocul Immunol Inflamm, 2022; 30(1):223–230; doi: 10.1080/09273948.2020.1791346
24.
DoychevaD, ZierhutM, BlumenstockG, et al.Immunomodulatory therapy with tumour necrosis factor α inhibitors in children with antinuclear antibody-associated chronic anterior uveitis: Long-term results. Br J Ophthalmol, 2014; 98(4):523–528; doi: 10.1136/bjophthalmol-2013-303935
25.
DeitchI, AmerR, Tomkins-NetzerO, et al.The effect of anti-tumor necrosis factor alpha agents on the outcome in pediatric uveitis of diverse etiologies. Graefes Arch Clin Exp Ophthalmol, 2018; 256(4):801–808; doi: 10.1007/s00417-018-3928-6
26.
CecchinV, ZanninME, FerrariD, et al.Longterm safety and efficacy of adalimumab and infliximab for uveitis associated with juvenile idiopathic arthritis. J Rheumatol, 2018; 45(8):1167–1172; doi: 10.3899/jrheum.171006
27.
Atienza-MateoB, Martín-VarillasJL, Calvo-RíoV, et al.Comparative study of infliximab versus adalimumab in refractory uveitis due to Behçet’s disease: National multicenter study of 177 cases. Arthritis Rheumatol, 2019; 71(12):2081–2089; doi: 10.1002/art.41026
28.
TakeuchiM, UsuiY, NambaK, et al.Ten-year follow-up of infliximab treatment for uveitis in Behçet disease patients: A multicenter retrospective study. Front Med (Lausanne), 2023; 10:1095423; doi: 10.3389/fmed.2023.1095423
29.
TakeuchiM, KezukaT, SugitaS, et al.Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Behçet’s disease: A multicenter study. Ophthalmology, 2014; 121(10):1877–1884; doi: 10.1016/j.ophtha.2014.04.042
30.
SimoniniG, TaddioA, CattaliniM, et al.Superior efficacy of adalimumab in treating childhood refractory chronic uveitis when used as first biologic modifier drug: Adalimumab as starting anti-TNF-α therapy in childhood chronic uveitis. Pediatr Rheumatol Online J, 2013; 11:16; doi: 10.1186/1546-0096-11-16
31.
Martín-VarillasJL, Sanchez-BilbaoL, Calvo-RíoV, et al.Long-term follow-up of certolizumab pegol in uveitis due to immune-mediated inflammatory diseases: Multicentre study of 80 patients. RMD Open, 2022; 8(2):e002693; doi: 10.1136/rmdopen-2022-002693
32.
Martín-VarillasJL, Atienza-MateoB, Calvo-RioV, et al.; Ricardo Blanco on behalf of the Spanish Collaborative Group of Refractory Behçet’s Disease. Long-term follow-up and optimization of infliximab in refractory uveitis due to Behçet disease: National study of 103 White patients. J Rheumatol, 2021; 48(5):741–750; doi: 10.3899/jrheum.200300
33.
MalekiA, SahawnehHF, MaL, et al.Infliximab therapy in patients with noninfectious intermediate uveitis resistant to conventional immunomodulatory therapy. Retina, 2017; 37(5):836–843; doi: 10.1097/IAE.0000000000001269
34.
KotaniemiK, SäiläH, KautiainenH. Long-term efficacy of adalimumab in the treatment of uveitis associated with juvenile idiopathic arthritis. Clin Ophthalmol, 2011; 5:1425–1429; doi: 10.2147/OPTH.S23646
35.
KimBH, ParkUC, ParkSW, et al.Ultra-widefield fluorescein angiography to monitor therapeutic response to adalimumab in Behcet’s uveitis. Ocul Immunol Inflamm, 2022; 30(6):1347–1353; doi: 10.1080/09273948.2021.1872652
36.
García-De-VicuñaC, Díaz-LlopisM, SalomD, et al.Usefulness of adalimumab in the treatment of refractory uveitis associated with juvenile idiopathic arthritis. Mediators Inflamm, 2013; 2013:560632; doi: 10.1155/2013/560632
37.
FabianiC, VitaleA, EmmiG, et al.Efficacy and safety of adalimumab in Behçet’s disease-related uveitis: A multicenter retrospective observational study. Clin Rheumatol, 2017; 36(1):183–189; doi: 10.1007/s10067-016-3480-x
38.
ErckensRJ, MostardRL, WijnenPA, et al.Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis. Graefes Arch Clin Exp Ophthalmol, 2012; 250(5):713–720; doi: 10.1007/s00417-011-1844-0
39.
DobnerBC, MaxR, BeckerMD, et al.A three-centre experience with adalimumab for the treatment of non-infectious uveitis. Br J Ophthalmol, 2013; 97(2):134–138; doi: 10.1136/bjophthalmol-2011-301401
40.
CantiniF, NiccoliL, NanniniC, et al.Efficacy of infliximab in refractory Behçet’s disease-associated and idiopathic posterior segment uveitis: A prospective, follow-up study of 50 patients. Biologics, 2012; 6:5–12; doi: 10.2147/BTT.S27343
41.
TosiGM, SotaJ, VitaleA, et al.Efficacy and safety of certolizumab pegol and golimumab in the treatment of non-infectious uveitis. Clin Exp Rheumatol, 2019; 37(4):680–683.
42.
KruhJN, YangP, SuelvesAM, et al.Infliximab for the treatment of refractory noninfectious uveitis: A study of 88 patients with long-term follow-up. Ophthalmology, 2014; 121(1):358–364; doi: 10.1016/j.ophtha.2013.07.019
43.
KimM, WonJY, ChoiSY, et al.Anti-TNFα treatment for HLA-B27-positive ankylosing spondylitis-related uveitis. Am J Ophthalmol, 2016; 170:32–40; doi: 10.1016/j.ajo.2016.07.016
44.
FabianiC, VitaleA, RiganteD, et al.Efficacy of anti-tumour necrosis factor-α monoclonal antibodies in patients with non-infectious anterior uveitis. Clin Exp Rheumatol, 2019; 37(2):301–305.
45.
SuiY, SunJW, ZhangCS, et al.Adalimumab combined with dexamethasone intravitreal implant in the treatment of refractory noninfectious uveitis macular edema. Guoji Yanke Zazhi (Int Eye Sci), 2024; 21(1):36–41; doi: 10.3980/j.issn.1672-5123.2024.1.07
46.
RamananAV, DickAD, JonesAP, et al.; SYCAMORE Study Group. Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis. N Engl J Med, 2017; 376(17):1637–1646; doi: 10.1056/NEJMoa1614160
47.
QuartierP, BaptisteA, DespertV, et al.ADJUVITE: A double-blind, randomised, placebo-controlled trial of adalimumab in early onset, chronic, juvenile idiopathic arthritis-associated anterior uveitis. Ann Rheum Dis, 2018; 77(7):1003–1011; doi: 10.1136/annrheumdis-2017-212089
48.
NguyenQD, MerrillPT, JaffeGJ, et al.Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): A multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet, 2016; 388(10050):1183–1192; doi: 10.1016/S0140-6736(16)31339-3
49.
MackensenF, HeinzC, JakobE, et al.Randomized controlled study to evaluate the efficacy of adalimumab in patients with different forms of refractory uveitis. Ocul Immunol Inflamm, 2018; 26(7):1015–1022; doi: 10.1080/09273948.2017.1411518
50.
JaffeGJ, DickAD, BrézinAP, et al.Adalimumab in patients with active noninfectious uveitis. N Engl J Med, 2016; 375(10):932–943; doi: 10.1056/NEJMoa1509852
51.
MingS, XieK, HeH, et al.Efficacy and safety of adalimumab in the treatment of non-infectious uveitis: A meta-analysis and systematic review. Drug Des Devel Ther, 2018; 12:2005–2016; doi: 10.2147/DDDT.S160431
52.
SharmaSM, DamatoE, HinchcliffeAE, et al.Long-term efficacy and tolerability of TNFα inhibitors in the treatment of non-infectious ocular inflammation: An 8-year prospective surveillance study. Br J Ophthalmol, 2021; 105(9):1256–1262; doi: 10.1136/bjophthalmol-2018-312767
53.
Prieto-PeñaD, Calderón-GoerckeM, AdánA, et al.Efficacy and safety of certolizumab pegol in pregnant women with uveitis. Recommendations on the management with immunosuppressive and biologic therapies in uveitis during pregnancy. Clin Exp Rheumatol, 2021; 39(1):105–114; doi: 10.55563/clinexprheumatol/j9ysbm
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
